https://www.ensayosclinicosroche.es2026-01-14https://www.ensayosclinicosroche.es/es/trials.html2025-06-06https://www.ensayosclinicosroche.es/es/trials/uncategorized.html2020-11-03https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-evaluating-safety--pharmacokinetics--and-therapeutic-act.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-gdc-9545-alone-or-in-combination-with-palbociclib-and.html2025-02-28https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-multiple-immunothe.html2025-02-12https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-ipatasertib-in-combination-with-paclitaxel-as-a-treat.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-pertuzumab-in-addition-to-chemotherapy-and-trastuzuma.html2022-04-25https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-atezolizumab-and-paclitaxel-versus-placebo-and-paclit.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-the-efficacy-and-safety-of-atezolizumab-plus-chemothe.html2025-10-08https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-to-evaluate-the-efficacy-and-safety-of-trastuzu-87572.html2026-03-25https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-to-evaluate-the-safety-and-efficacy-of-ipataser-98538.html2024-10-31https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-to-evaluate-the-efficacy-and-safety-of-atezoliz-39916.html2024-11-06https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-trastuzumab-emtansine-versus-trastuzumab-as-adjuvant-.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-to-investigate-atezolizumab-and-chemotherapy-compared-wi.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-ipatasertib-plus-palbociclib-and-fulvestrant-28505.html2024-11-09https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-gdc-0077--75564.html2025-08-21https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-trastuzumab-emtansine--kadcyla--plus-pertuzu-91245.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-pertuzumab-in-combination-with-trastuzumab---50542.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-ipatasertib-in-combination-with-atezolizumab-93464.html2020-05-22https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-the-safety--efficacy--and-pharmacokinetics-o-75095.html2024-12-16https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-evaluating-the-efficacy--safety--and-pharmacoki-19834.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-gdc-9545--28702.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-trastuzumab-emtansine-in-combination-with-at-19708.html2025-10-08https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-multiple--68522.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-adjuvant--70278.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-adjuvant--58545.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-to-evaluate-patient-preference-for-home-adminis-86302.html2026-03-03https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-inavolisi-04316.html2024-01-10https://www.ensayosclinicosroche.es/es/trials/cancer/bc/the-purpose-of-this-study-is-to-evaluate-the-efficacy-a-74702.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-of-ro7247669---nab-paclitaxel-compared-with-pem-15706.html2025-12-26https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-to-investigate-mechanisms-of-resistance-to-brea-16246.html2025-02-22https://www.ensayosclinicosroche.es/es/trials/cancer/bc/study-comparing-atezolizumab--anti-pd-l1-antibody--in-68166.html2025-06-18https://www.ensayosclinicosroche.es/es/trials/cancer/bc/a-study-evaluating-the-efficacy-and-safety-of-inavolisi-81795.html2026-01-08https://www.ensayosclinicosroche.es/es/trials/cancer/bc/to-study-the-effect-of-inavolisib-in-combination-with-f-35021.html2026-02-09https://www.ensayosclinicosroche.es/es/trials/cancer/leukemia/a-study-of-idasanutlin-with-cytarabine-versus-cytarabine-plus-pl.html2024-06-22https://www.ensayosclinicosroche.es/es/trials/cancer/leukemia/a-study-to-compare-the-efficacy-and-safety-of-obinutuzu-46860.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/leukemia/a-study-to-compare-the-efficacy-and-safety-of-a-combine-77420.html2026-01-27https://www.ensayosclinicosroche.es/es/trials/cancer/leukemia/a-dose-escalation-and-expansion-study-evaluating-the-sa-65126.html2024-10-02https://www.ensayosclinicosroche.es/es/trials/cancer/oc/a-study-of-atezolizumab-versus-placebo-in-combination-with-pacli.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/cancer/oc/an-observational-study-of-avastin--bevacizumab--in-pati-15217.htmlhttps://www.ensayosclinicosroche.es/es/trials/cancer/oc/a-study-evaluating-the-safety--pharmacokinetics-and-eff-46472.html2024-06-21https://www.ensayosclinicosroche.es/es/trials/cancer/oc/a-study-evaluating-the-efficacy-and-safety-of-biomarker-28995.html2025-03-19https://www.ensayosclinicosroche.es/es/trials/cancer/oc/a-clinical-study-of-cobimetinib-administered-in-combina-24843.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/crc/study-of-cobimetinib-in-combination-with-atezolizumab-and-bevaci.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/cancer/crc/a-phase-ib-study-to-evaluate-the-safety--efficacy--and--82576.html2025-04-08https://www.ensayosclinicosroche.es/es/trials/cancer/crc/a-study-evaluating-the-safety-and-efficacy-of-targeted--57345.html2025-09-04https://www.ensayosclinicosroche.es/es/trials/cancer/cca/a-study-of-tiragolumab-plus-atezolizumab-and-atezolizum-32500.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/pv.html2020-11-03https://www.ensayosclinicosroche.es/es/trials/cancer/a-study-in-participants-previously-enrolled-in-a-genentech-and-o.html2025-02-07https://www.ensayosclinicosroche.es/es/trials/cancer/bladder-cancer/study-of-atezolizumab-as-monotherapy-and-in-combination-with-pla.html2025-02-25https://www.ensayosclinicosroche.es/es/trials/cancer/bladder-cancer/a-study-evaluating-the-efficacy-and-safety-of-multiple--45851.html2025-01-04https://www.ensayosclinicosroche.es/es/trials/cancer/bladder-cancer/a-study-of-atezolizumab-versus-placebo-as-adjuvant-ther-94959.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-evaluating-the-efficacy-and-safety-of-divarasib.html2025-05-14https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-of-atezolizumab-compared-with-chemotherapy-in-treatment-.html2024-10-24https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-to-evaluate-efficacy-and-safety-of-multiple-targeted-the.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-of-multiple-immunotherapy-based-treatment-combinations-i0.html2025-02-21https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-of-neoadjuvant-atezolizumab-plus-chemotherapy-versus-pla.html2025-05-21https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-of-carboplatin-plus-etoposide-with-or-without-atezolizum.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-to-investigate-the-pharmacokinetics--efficacy---50110.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/alectinib-compared-with-chemotherapy-in-previously-treated-patie.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-of-tiragolumab-in-combination-with-atezolizumab-44503.html2026-01-29https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-comparing-alectinib-with-crizotinib-in-treatmen-47622.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/study-of-atezolizumab-in-combination-with-cabozantinib--77103.html2025-02-28https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-of-atezolizumab-and-tiragolumab-compared-with-d-48756.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/estudio-fase-iiib--de-un-solo-brazo-de-carboplatino-o-cisplatino.html2021-04-13https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-of-tiragolumab-in-combination-with-atezolizumab-98469.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-to-monitor-lung-cancer-patients-activity-and-as-96332.htmlhttps://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-to-compare-the-efficacy-and-safety-of-entrectin-60665.html2026-02-09https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-phase-iii--open-label-study-of-maintenance-lurbinecte-08813.html2025-07-26https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-to-evaluate-participant-and-healthcare-professi-70557.html2024-11-22https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-clinical-trial-to-look-at-how-well-atezolizumab-works--and-how.html2026-02-12https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-of-ro7247669-plus-platinum-based-chemotherapy-v-60649.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-to-evaluate-safety--tolerability--pharmacokinet-04290.html2025-03-11https://www.ensayosclinicosroche.es/es/trials/cancer/lung-cancer/a-study-evaluating-the-efficacy-and-safety-of-divarasib-53110.html2026-02-13https://www.ensayosclinicosroche.es/es/trials/cancer/multiple-myeloma/a-study-of-cobimetinib-administered-as-single-agent-and-in-combi.html2024-06-22https://www.ensayosclinicosroche.es/es/trials/cancer/multiple-myeloma/dose-escalation-study-of-bfcr4350a-in-participants-with-relapsed.html2025-02-25https://www.ensayosclinicosroche.es/es/trials/cancer/multiple-myeloma/a-study-evaluating-the-safety-and-pharmacokinetics-of-e-50454.html2025-07-07https://www.ensayosclinicosroche.es/es/trials/cancer/multiple-myeloma/a-study-evaluating-the-safety--pharmacokinetics--and-ac-86713.html2025-07-10https://www.ensayosclinicosroche.es/es/trials/cancer/multiple-myeloma/a-study-evaluating-the-safety-and-efficacy-of-multiple--63288.html2025-02-25https://www.ensayosclinicosroche.es/es/trials/cancer/multiple-myeloma/a-study-evaluating-the-efficacy-and-safety-of-cevostama-15661.html2025-02-19https://www.ensayosclinicosroche.es/es/trials/cancer/multiple-myeloma/a-study-evaluating-safety--tolerability--and-clinical-a-92792.html2025-02-27https://www.ensayosclinicosroche.es/es/trials/cancer/rcc/a-study-of-atezolizumab-as-adjuvant-therapy-in-participants-with.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/rcc/a-study-of-atezolizumab-plus-bevacizumab-versus-active--52983.html2025-04-08https://www.ensayosclinicosroche.es/es/trials/cancer/rcc/a-study-of-atezolizumab-in-combination-with-cabozantini-46186.html2026-02-20https://www.ensayosclinicosroche.es/es/trials/cancer/rcc/a-study-of-atezolizumab-in-combination-with-bevacizumab-07419.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/rcc/a-study-of-immune-checkpoint-inhibitor-combinations-wit-47221.html2025-03-06https://www.ensayosclinicosroche.es/es/trials/cancer/skin-cancer/cobimetinib--targeted-therapy--plus-atezolizumab--immunotherapy-.html2026-03-25https://www.ensayosclinicosroche.es/es/trials/cancer/skin-cancer/a-study-evaluating-the-safety-and-efficacy-of-cobimetin-52731.html2024-10-02https://www.ensayosclinicosroche.es/es/trials/cancer/skin-cancer/a-phase-ib-study-to-evaluate-safety-and-therapeutic-act-73518.html2024-10-04https://www.ensayosclinicosroche.es/es/trials/cancer/skin-cancer/a-study-comparing-vemurafenib-versus-vemurafenib-plus-c-99807.html2024-06-21https://www.ensayosclinicosroche.es/es/trials/cancer/skin-cancer/a-study-of-ro7293583-in-participants-with-unresectable--00455.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/cancer/hepatocellular-carcinoma/a-study-of-atezolizumab-in-combination-with-bevacizumab-compared.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/cancer/hepatocellular-carcinoma/a-study-of-atezolizumab-in-combination-with-bevacizumab-40482.html2025-06-12https://www.ensayosclinicosroche.es/es/trials/cancer/hepatocellular-carcinoma/a-study-of-atezolizumab-with-lenvatinib-or-sorafenib-ve-22252.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/hepatocellular-carcinoma/a-study-evaluating-atezolizumab-and-bevacizumab--with-o-66135.html2026-01-01https://www.ensayosclinicosroche.es/es/trials/cancer/Head_and_Neck_Cancer/a-study-of-atezolizumab--antipd-l1-antibody--as-adjuvant-therapy.html2025-07-07https://www.ensayosclinicosroche.es/es/trials/cancer/study-to-evaluate-the-therapeutic-activity-of-ro6874281-as-a-com.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/Brain_Tumor/study-of-rxdx-101-in-children-with-recurrent-or-refractory-solid.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/pancreatic-cancer/a-study-of-multiple-immunotherapy-based-treatment-combinations-i2.html2025-02-07https://www.ensayosclinicosroche.es/es/trials/cancer/a-safety-and-efficacy-extension-study-of-pertuzumab-in-patients-.html2024-09-25https://www.ensayosclinicosroche.es/es/trials/cancer/a-phase-ii-randomized-study-comparing-the-efficacy-and-safety-of.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/an-extension--rollover--study-of-vemurafenib-in-participants-wit.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/cancer/safety-and-pharmacokinetics-of-cobimetinib-in-pediatric-and-youn.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/safety-and-pharmacokinetics--pk--of-escalating-doses-of-mtig7192.html2024-12-06https://www.ensayosclinicosroche.es/es/trials/cancer/prostate-cancer/a-study-of-atezolizumab--anti-pd-l1-antibody--in-combination-wit.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/cancer/prostate-cancer/ipatasertib-plus-abiraterone-plus-prednisone-prednisolone--relat.html2025-02-10https://www.ensayosclinicosroche.es/es/trials/cancer/prostate-cancer/a-study-evaluating-the-safety--efficacy-and-pharmacokin-79210.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/gc.html2020-11-03https://www.ensayosclinicosroche.es/es/trials/cancer/a-study-of-atezolizumab-in-locally-advanced-or-metastat-72736.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/an-extension-study-to-provide-continued-bevacizumab-therapy-to-p.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/cancer/fmi.html2024-10-25https://www.ensayosclinicosroche.es/es/trials/cancer/alk-rearranged-non-small-cell-lung-cancer/a-dose-escalation-and-expansion-study-of-ro7121661--a-p-10103.html2025-05-21https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/an-open-label--single-arm-study-of-obinutuzumab-short-d-96747.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-to-evaluate-the-safety-and-efficacy-of-polatuzu-71789.html2026-01-27https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-comparing-maintenance-subcutaneous-rituximab-wi-80076.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-to-evaluate-the-safety--pharmacokinetics-and-pr-54653.html2025-09-11https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-phase-ib-ii-study-investigating-the-safety--tolerabil-91932.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/an-open-label-phase-lb-study-of-ro7082859-and-atezolizumab-in-ad.html2022-10-19https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-of-ro7082859-in-combination-with-rituximab-or-obinutuzum.html2025-06-11https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-comparing-the-efficacy-and-safety-of-polatuzumab-vedotin.html2022-08-29https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-dose-escalation-study-of-ro7082859-as-a-single-agent-and-in-co.html2022-10-19https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-of-obinutuzumab--polatuzumab-vedotin--and-lenalidomide-i.html2022-03-14https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-evaluating-the-safety--pharmacokinetics--and-ef-94381.html2025-02-12https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-phase-iii-study-evaluating-glofitamab-in-combination--62070.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-evaluating-the-efficacy-and-safety-of-mosunetuz-89423.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-to-evaluate-the-safety-and-efficacy-of-glofitam-14259.htmlhttps://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-evaluating-the-safety--pharmacokinetics--and-ef-62272.html2025-01-11https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-to-evaluate-glofitamab---chemoimmunotherapy-in--23052.html2025-01-14https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/an-open-label-study-comparing-glofitamab-and-polatuzuma-51322.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/non-hodgkins-lymphoma/a-study-to-evaluate-glofitamab-as-a-single-agent-vs--in-75996.html2025-03-08https://www.ensayosclinicosroche.es/es/trials/cancer/a-study-of-the-safety--pharmacokinetics--and-therapeuti-98047.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/a-study-in-patients-previously-enrolled-in-a-genentech--39726.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/a-study-evaluating-the-safety--tolerability--pharmacoki-00443.html2024-12-21https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/a-study-to-evaluate-the-safety--tolerability--pharmacok-12037.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/a-study-to-evaluate-safety-and-anti-tumor-activity-of-r-73278.html2025-03-06https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/a-study-to-evaluate-the-safety-and-tolerability-of-ro72-99201.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/a-study-of-gdc-0919-and-atezolizumab-combination-treatm-85004.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/a-study-to-assess-the-safety-and-pharmacokinetics-of-mo-12948.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/a-study-of-ro6958688-in-participants-with-locally-advan-08287.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/tumor-agnostic-precision-immuno-oncology-and-somatic-ta-50851.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/a-study-to-evaluate-the-safety-and-tolerability-of-ro72-03496.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/a-study-to-evaluate-safety--pharmacokinetics-and-anti-t-88927.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/a-study-to-evaluate-safety--pharmacokinetics--and-preli-17129.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/a-study-to-evaluate-the-safety--pharmacokinetics--and-a-03859.html2025-03-06https://www.ensayosclinicosroche.es/es/trials/cancer/solid-tumors/a-study-of-adjuvant-atezolizumab-or-atezolizumab-plus-t-86863.html2025-07-08https://www.ensayosclinicosroche.es/es/trials/cancer/high-grade-glioma/a-study-of-bevacizumab--avastin--in-combination-with-te-29856.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/cancer/esophageal-squamous-cell-carcinoma/a-study-of-atezolizumab-with-or-without-tiragolumab-in--42508.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/cancer/a-study-exploring-the-safety-and-efficacy-of-atezolizumab-in-com.html2023-01-09https://www.ensayosclinicosroche.es/es/trials/cancer/clinical-impact-and-utility-of-digital-health-solutions-26657.htmlhttps://www.ensayosclinicosroche.es/es/trials/cancer/a-study-assessing-the-safety-and-efficacy-of-adding-ipa-52566.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/cancer/a-study-to-evaluate-the-safety--tolerability--processing-by-the-.html2024-12-09https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/jia/a-study-of-decreased-dose-frequency-in-participants-with-systemi.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/jia/a-study-of-subcutaneously--sc--administered-tocilizumab-80633.html2024-06-22https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/jia/a-study-of-subcutaneously-administered-tocilizumab-in-p-36947.html2024-06-22https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/ra.html2020-11-05https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/ulcerative-colitis/a-phase-i-study-of-etrolizumab-followed-by-open-label-extension-.html2024-12-28https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/ulcerative-colitis/a-study-comparing-the-efficacy-and-safety-of-etrolizumab-to-infl.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/ulcerative-colitis/a-study-to-evaluate-the-efficacy--safety--and-pharmacokinetics-o.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/ulcerative-colitis/study-for-participants-with-ulcerative-colitis-previously-enroll.html2024-10-24https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/ulcerative-colitis/an-extension-study-to-evaluate-the-long-term-safety-and-37359.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/crohn-s-disease/a-study-to-assess-whether-etrolizumab-is-a-safe-and-effective-tr.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/crohn-s-disease/a-study-to-assess-the-efficacy-and-safety-of-induction-therapy.html2025-05-16https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/crohn-s-disease/study-to-test-the-effectiveness-and-safety.html2025-05-16https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/sle/study-of-the-safety-and-efficacy-of-gdc-0853-in-participants-wit.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/sle/a-study-to-evaluate-the-efficacy-and-safety-of-obinutuz-62318.html2026-03-12https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/sle/a-first-in-human-study-to-investigate-the-safety--toler-46873.html2025-09-18https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/an-extension-study-of-gdc-0853-in-participants-with-moderate-to-.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/systemic-sclerosis/a-study-to-evaluate-the-safety--tolerability--and-pharm-79881.html2025-01-23https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/ibd.html2024-10-25https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/efficacy-and-safety-study-of-satralizumab--sa237--as-ad-86851.html2025-07-17https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/pnh/a-study-evaluating-the-efficacy-and-safety-of-crovalima-16124.html2025-02-12https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/pnh/a-phase-iii-study-evaluating-the-efficacy-and-safety-of-15078.html2025-02-08https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/ln/a-study-to-evaluate-the-efficacy-and-safety-of-obinutuz-33293.html2025-07-14https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/ln/a-study-to-evaluate-the-efficacy--safety--and-pharmacok-25573.html2026-03-04https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/neuromyelitis-optica-spectrum-disorders/a-study-to-evaluate-the-safety-and-efficacy-of-satraliz-27030.html2024-10-22https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/primary-membranous-nephropathy/a-study-evaluating-the-efficacy-and-safety-of-obinutuzu-42023.html2025-03-25https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/myasthenia-gravis-iab/a-study-to-evaluate-efficacy--safety--pharmacokinetics--13414.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/a-clinical-trial-of-omalizumab-in-participants-with-chronic-rhin0.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/an-extension-study-of-omalizumab-in-participants-with-chronic-rh.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/multiple-sclerosis/a-study-to-investigate-the-safety--tolerability--and-pr-15846.html2025-06-12https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/multiple-sclerosis/a-pharmacokinetics--pk---pharmacodynamics--pd---safety--83549.html2026-01-28https://www.ensayosclinicosroche.es/es/trials/autoimmune-disorder/multiple-sclerosis/a-study-to-evaluate-the-safety--pharmacokinetics--pharm-05385.html2026-03-05https://www.ensayosclinicosroche.es/es/trials/eye-disorder/dme/a-study-to-evaluate-the-efficacy-and-safety-of-ro686746-59371.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/eye-disorder/glaucoma.html2018-11-21https://www.ensayosclinicosroche.es/es/trials/eye-disorder/amd/extension-study-for-the-port-delivery-system-with-ranib-90123.html2025-09-18https://www.ensayosclinicosroche.es/es/trials/eye-disorder/amd/a-study-to-evaluate-the-safety--tolerability--pharmacok-30793.htmlhttps://www.ensayosclinicosroche.es/es/trials/eye-disorder/amd/a-study-to-evaluate-the-long-term-safety-and-tolerabili-60381.html2024-12-12https://www.ensayosclinicosroche.es/es/trials/eye-disorder/wamd/a-study-to-evaluate-the-efficacy-and-safety-of-faricima-34628.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/eye-disorder/wamd/a-study-to-evaluate-the-efficacy-and-safety-of-faricima-82370.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/eye-disorder/wamd/a-study-of-36-week-refill-exchanges-of-port-delivery-sy-66037.html2026-02-17https://www.ensayosclinicosroche.es/es/trials/eye-disorder/uveitic-macular-edema/ro7200220-in-participants-with-uveitic-macular-edema-91001.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/eye-disorder/neovascular-age-related-macular-degeneration/a-study-to-determine-the-efficacy--safety--and-durabili-18839.html2026-02-12https://www.ensayosclinicosroche.es/es/trials/muscle-and-peripheral-nerve-disease/sma/a-study-to-investigate-the-safety--tolerability--pharmacokinetic1.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/muscle-and-peripheral-nerve-disease/sma/a-study-to-investigate-the-safety-and-efficacy-of-ro720-92328.html2025-03-25https://www.ensayosclinicosroche.es/es/trials/muscle-and-peripheral-nerve-disease/dmd/an-open-label-study-to-assess-the-efficacy-and-safety-o-12382.html2025-04-08https://www.ensayosclinicosroche.es/es/trials/muscle-and-peripheral-nerve-disease/muscular-dystrophy.html2020-11-05https://www.ensayosclinicosroche.es/es/trials/infectious-diseases/hbv.html2020-11-05https://www.ensayosclinicosroche.es/es/trials/infectious-diseases/hbv/a-trial-to-evaluate-the-efficacy-and-safety-of-multiple-42976.htmlhttps://www.ensayosclinicosroche.es/es/trials/infectious-diseases/influenza/study-to-assess-efficacy-and-safety-of-baloxavir-marbox-94137.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/infectious-diseases/influenza/study-to-assess-the-efficacy-of-baloxavir-marboxil-vers-02272.html2025-01-27https://www.ensayosclinicosroche.es/es/trials/infectious-diseases/influenza/study-to-assess-the-safety--pharmacokinetics--and-effic-62594.html2024-06-22https://www.ensayosclinicosroche.es/es/trials/infectious-diseases/bacterial-infection/study-to-investigate-the-safety--tolerability--and-pharmacokinet.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/infectious-diseases/covid-19-pneumonia/a-study-to-evaluate-the-safety-and-efficacy-of-mstt1041-69681.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-study-of-crenezumab-versus-placebo-to-evaluate-the-efficacy-an.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-efficacy-and-safety-of-ro7105705-in-pati.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/safety-and-efficacy-study-of-gantenerumab-in-participants-with-e.html2024-06-22https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/efficacy-and-safety-study-of-gantenerumab-in-participants-with-e.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/cread-study--a-study-of-crenezumab-versus-placebo-to-ev-21662.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-study-of-mtau9937a-in-patients-with-moderate-alzheime-94595.html2024-09-25https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-study-of-gantenerumab-in-participants-with-mild-alzhe-16675.html2024-06-22https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-study-of-gantenerumab-in-participants-with-prodromal--48625.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-safety-and-tolerability-of-long-88018.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-pharmacodynamic--pd--effects-of-20860.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/brainshuttle-ad--a-multiple-ascending-dose-study-to-inv-79871.html2025-03-08https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-safety--tolerability--and-effic-66535.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-efficacy-and-safety-of-gantener-84528.html2024-08-30https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-study-to-evaluate-the-safety-and-biomarker-effects-of-20108.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-clinical-trial-of-trontinemab-in-participants-with-ea-85398.html2026-01-27https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/a-study-of-trontinemab-in-participants-with-early-sympt-02194.html2026-01-27https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/ad/screening-study-to-determine-individuals-with-potential-76396.html2025-12-20https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/als.html2020-11-05https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/pd/a-study-to-evaluate-the-efficacy-and-safety-of-intraven-35605.html2025-01-22https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/multiple-sclerosis/study-to-evaluate-the-effectiveness-and-safety-of-ocrelizumab-in.html2025-01-16https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/multiple-sclerosis/this-is-an-extension-study-of-the-roche-p-trial-to-inve-91061.html2024-11-08https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-to-evaluate-ocrelizumab-treatment-in-participants-with-p.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-of-ocrelizumab-in-participants-with-relapsing-r-56554.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-to-evaluate-the-efficacy-and-safety-of-ocrelizu-22490.html2025-01-28https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-to-evaluate-the-efficacy-and-safety-of-fenebrut-03470.html2023-06-14https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-to-evaluate-the-efficacy--safety-and-pharmacoki-18428.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/multiple-sclerosis/a-study-of-ocrelizumab-in-participants-with-primary-pro-36628.htmlhttps://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/multiple-sclerosis/a-phase-iii--non-inferiority--randomized--open-label--p-91560.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/multiple-sclerosis/a-rollover-study-to-evaluate-the-long-term-safety-and-e-52490.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/hd/a-study-to-evaluate-the-efficacy-and-safety-of-intrathe-26435.html2024-09-01https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/hd/an-open-label-extension-study-to-evaluate-the-long-term-82935.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/neurodegenerative-disorder/hd/a-study-to-evaluate-the-safety--biomarkers--and-efficac-41200.html2025-04-08https://www.ensayosclinicosroche.es/es/trials/neurodevelopmental-disorder/autism-spectrum-disorder/a-study-of-balovaptan-in-adults-with-autism-spectrum-disorder-wi.html2024-06-21https://www.ensayosclinicosroche.es/es/trials/neurodevelopmental-disorder/angelman-syndrome/a-study-to-investigate-the-safety--tolerability--pharma-19556.html2026-02-04https://www.ensayosclinicosroche.es/es/trials/neurodevelopmental-disorder/angelman-syndrome/study-to-investigate-the-pharmacokinetics-and-safety-an-84203.html2025-03-21https://www.ensayosclinicosroche.es/es/trials/neurodevelopmental-disorder/autism/a-12-week-placebo-controlled-study-to-investigate-the-e-88629.html2025-01-29https://www.ensayosclinicosroche.es/es/trials/respiratory-disorder/ipf/efficacy--safety--and-tolerability-study-of-pirfenidone-in-combi.html2024-08-31https://www.ensayosclinicosroche.es/es/trials/respiratory-disorder/ipf/a-study-evaluating-the-efficacy-and-safety-of-vixarelim-89139.html2025-03-27https://www.ensayosclinicosroche.es/es/trials/respiratory-disorder/respiratory-other.html2018-12-20https://www.ensayosclinicosroche.es/es/trials/respiratory-disorder/asthma.html2018-12-20https://www.ensayosclinicosroche.es/es/trials/kidney-disorder/renal-failure.html2020-11-05https://www.ensayosclinicosroche.es/es/trials/kidney-disorder/iga-nephropathy/a-study-to-evaluate-the-efficacy-and-safety-of-ro743465-06097.html2025-09-10https://www.ensayosclinicosroche.es/es/trials/metabolic-disorder/t1d.html2020-11-05https://www.ensayosclinicosroche.es/es/trials/metabolic-disorder/Liver_Failure.html2020-11-05https://www.ensayosclinicosroche.es/es/trials/metabolic-disorder/dr/a-study-to-investigate-the-efficacy-and-safety-of-rg777-36226.html2024-09-26https://www.ensayosclinicosroche.es/es/trials/psychiatric-disorder/schizophrenia/a-study-to-assess-the-effects-of-ro6889450-in-participa-51328.htmlhttps://www.ensayosclinicosroche.es/es/trials/hematologic-diseases/a-study-evaluating-the-safety--pharmacokinetics--pharma-03990.html2026-03-03https://www.ensayosclinicosroche.es/es/trials/hematologic-diseases/myelodysplastic-syndrome.html2020-11-05https://www.ensayosclinicosroche.es/es/trials/hematologic-diseases/Hemophilia/a-study-to-evaluate-the-safety-and-tolerability-of-prophylactic-.html2023-03-29https://www.ensayosclinicosroche.es/es/trials/hematologic-diseases/Hemophilia/a-study-to-evaluate-the-efficacy--safety--and-pharmacok-78611.html2023-03-29https://www.ensayosclinicosroche.es/es/trials/hematologic-diseases/Hemophilia/a-study-to-evaluate-the-efficacy--safety--pharmacokinet-06605.html2023-03-29https://www.ensayosclinicosroche.es/es/trials/hematologic-diseases/Hemophilia/a-study-of-emicizumab-administered-subcutaneously--sc---47981.html2023-03-29https://www.ensayosclinicosroche.es/es/trials/hematologic-diseases/Hemophilia/a-clinical-trial-to-evaluate-prophylactic-emicizumab-ve-59481.html2023-03-29https://www.ensayosclinicosroche.es/es/trials/blood-disorder/sickle-cell-disease_msm_moved.html2024-10-25https://www.ensayosclinicosroche.es/es/trials/blood-disorder/sickle-cell-disease/a-study-evaluating-the-efficacy--safety--pharmacokineti-50959_msm_moved.html2021-12-09https://www.ensayosclinicosroche.es/es/trials/blood-disorder/sickle-cell-disease/a-study-evaluating-the-efficacy--safety--pharmacokineti-50959.html2021-11-09https://www.ensayosclinicosroche.es/es/trials/blood-disorder/atypical-hemolytic-uremic-syndrome/a-study-evaluating-the-efficacy--safety--pharmacokineti-29406.html2023-03-23https://www.ensayosclinicosroche.es/es/trials/blood-disorder/blood-platelet-disorder/a-study-to-assess-the-efficacy-and-safety-of-emicizumab-28219.html2025-09-10https://www.ensayosclinicosroche.es/es/trials/Hemophilia/hemophilia-a/a-study-to-evaluate-the-safety--tolerability--pharmacok-88545.html2025-09-10https://www.ensayosclinicosroche.es/es/faq.html2020-09-02https://www.ensayosclinicosroche.es/es/faq/what-is-a-clinical-trial.html2023-05-09https://www.ensayosclinicosroche.es/es/faq/why-should-i-consider-taking-part-in-a-clinical-trial.html2020-08-06https://www.ensayosclinicosroche.es/es/faq/roche-in-clinical-trials.html2023-05-09https://www.ensayosclinicosroche.es/es/error.html2018-11-21https://www.ensayosclinicosroche.es/es/error/404.html2024-10-18https://www.ensayosclinicosroche.es/es/error/403.html2024-10-18https://www.ensayosclinicosroche.es/es/error/500.html2024-10-18https://www.ensayosclinicosroche.es/es/privacy-policy.html2018-11-21https://www.ensayosclinicosroche.es/es/glossary-terms.html2021-06-24https://www.ensayosclinicosroche.es/es/About.html2019-03-04https://www.ensayosclinicosroche.es/es/sitemap.html2018-11-21https://www.ensayosclinicosroche.es/es/nota-sobre-el-covid-19.html2020-04-28https://www.ensayosclinicosroche.es/es/disease-area-overview.html2022-01-31https://www.ensayosclinicosroche.es/es/new-solr-search.html2024-02-16